

Activity Outline
**Topics in Public Health: Pills, Patches and Rings Oh My! How pharmacists can navigate the road to expand
contraception care and STI screening**
July 19, 2019
Webinar

Activity Coordinator
Ashlee Januszewicz
Ashlee.Januszewicz@fda.hhs.gov

Series Description

This series will educate PHS health professionals about topics that are pertinent to their roles within the various agencies within the Department of Health and Human Services and other Public Health Service agencies by presenting topics that directly relate to the HHS Strategic Plan, the Secretary's Strategic Initiatives, current topics for DHHS OPDIVs who utilize PHS health professionals, and/or other topics directly related to the advancement of public health.

Lecture Description

A review of contraceptive care provided through the pharmacy managed Contraceptive clinic at Phoenix Indian Medical Center. This review will discuss an ambulatory care pharmacists' role in expanding contraceptive care to AI/AN as well as a discussion of the US MEC and US SPR as clinical tools and references when making contraceptive care decisions, special populations, clinical pearls and some lessons learned.

References

- Curtis KM, Jatlaoui TC, Tepper NK, et al. U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65(No. RR-4):1–66. DOI: <http://dx.doi.org/10.15585/mmwr.rr6504a1>External.
- Centers for Disease Control and Prevention. https://www.cdc.gov/reproductivehealth/contraception/mmwr/spr/summary.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Freproductivehealth%2Fcontraception%2Fusspr.htm
- Curtis KM, Tepper NK, Jatlaoui TC, et al. U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep 2016;65(No. RR-3):1–104. DOI: <http://dx.doi.org/10.15585/mmwr.rr6503a1>External.
- Centers for Disease Control and Prevention. https://www.cdc.gov/mmwr/volumes/65/rr/rr6503a1_appendix.htm?c_cid=journal_search_promotion_2018
- Centers for Disease Control and Prevention. <https://www.cdc.gov/std/tg2015/screening-recommendations.htm>
- Centers for Disease Control and Prevention. <https://www.cdc.gov/std/stats17/default.htm>

Series Objectives

- Describe scientific evidence supporting the HHS Initiatives, Surgeon General Priorities or any other public health concern
- Explain the multi-disciplinary approach in addressing public health issues
- Identify public health concerns.
- Identify ways Public Health Professionals can impact public health issues.

Learning Objectives After completion of this activity, the participant will be able to:

- Describe examples of shared decision making when selecting contraceptive options with patients
- Demonstrate proper use of the US MEC and US SPR for selection and safe/proper use of contraceptive options in women
- Review important counseling points on contraceptives and STI prevention
- Determine contraceptive options for special populations

Target Audience

This activity is intended for physicians, pharmacists, nurses, and other public health medical professionals interested in learning more about the initiatives other advances in public health.

Agenda

Lecture 1 July 19, 2019

| Time | Topic | Speaker |
|----------------|--|-------------|
| 2:00 - 3:00 PM | Pills, Patches and Rings Oh My! How pharmacists can navigate the road to expand contraception care and STI screening | Thalia Vega |

Continuing Education Accreditation



JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, FDA Center for Drug Evaluation and Research is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



IPCE CREDIT™

This activity was planned by and for the healthcare team, and learners will receive 1.00 Interprofessional Continuing Education (IPCE) credit(s) for learning and change.

CME

FDA Center for Drug Evaluation and Research designates this live activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE

This knowledge-based activity has been assigned ACPE Universal Activity Number JA0002895-0000-19-014-L04-P, and ACPE Universal Activity Number JA0002895-0000-19-014-L04-T for 1.00 contact hour(s).

CNE

FDA Center for Drug Evaluation and Research designates this activity for 1.00 contact hour(s).

CPH

Up to 1.00 CPH Recertification Credits may be earned at this event.

Requirements for Receiving CE Credit

Physicians, pharmacists, nurses, pharmacist techs, and those claiming non-physician CME: participants must attest to their attendance and complete the final activity evaluation via the CE Portal (ceportal.fda.gov). For multi-day activities, participants must attest to their attendance and complete the faculty evaluation each day. Final activity evaluations must be completed within two weeks after the activity - no exceptions.

Pharmacists will need their NABP e-profile ID number as well as their DOB in MMDD format in order to claim CE credit.

Important Note regarding completion of evaluations and receiving credit

Attendees have 14 days from the last day of the activity to log in, complete the required evaluation(s) and attest to your attendance to claim credit. Physicians and nurses may then view/print statement of credit. Pharmacists should log into the CPE monitor 10 weeks after the last session of the activity to obtain their CE credit.

Disclosure

Faculty

- Vega, Thalia, Pharmacist, Phoenix Indian Medical Center *May reference off-label use.*

Planning Committee

- Alu, Susan, Pharm.D., Clinical Pharmacist, U.S. Public Health Service - nothing to disclose
- Begansky, Stephanie, PharmD, BCACP, Advanced Clinical Pharmacist, IHS - nothing to disclose
- Birch-Smith, Postelle, PharmD - nothing to disclose
- Brodhead, LeAnn, PharmD, Health Insurance Specialist, CMS - nothing to disclose

- ▣ CHIN, EDWARD, Medical Officer, DNDP - nothing to disclose
- ▣ Camilli, Sara, PharmD, , BCPS, Associate Director, FDA/CDER/OSE/DPV II - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Januszewicz, Ashlee, Pharm.D, Compounding Incidents Team Leader, FDA/CDER/OC/OU DLC - nothing to disclose
- ▣ Khatri, Sadhna, PharmD, MPH, MS, MEd, Regulatory Officer, FDA/CDER/OCD/PASE - nothing to disclose
- ▣ La, Thang, PharmD, MPH, Central Triage Unit supervisor, FDA/CDER/OSE/RSS - nothing to disclose
- ▣ Leung, Tamy, PharmD, MPH, BCPS, Accountable Care Organization Coordinator, Centers for Medicare and Medicaid - nothing to disclose
- ▣ Lucero, Karly, RN, DNP, MSN/eD, CCHP, Regional Field Medical Coordinator, DHS - nothing to disclose
- ▣ McClain, Rena, PharmD, CMS - nothing to disclose
- ▣ Nabavian, Sadaf, Senior Regulatory Project Manager, FDA - nothing to disclose
- ▣ WAGNER, LINDSAY, PharmD, Team Leader, FDA - nothing to disclose

CE Consultation and Accreditation Team

- ▣ Bryant, Traci, M.A.T., CE Consultant, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Giroux, Virginia, MSN, FNP-BC, Associate Director for Accreditation, FDA/CDER/OEP/DLOD - nothing to disclose
- ▣ Zawalick, Karen, CE Team Leader, FDA/CDER/OEP/DLOD - nothing to disclose

Registration Fee and Refunds

Registration is complimentary, therefore refunds are not applicable.